Mengyi Du
Overview
Explore the profile of Mengyi Du including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tang L, Zhang H, Zhou F, Wei Q, Du M, Wu J, et al.
Cancer Commun (Lond)
. 2024 Feb;
44(3):408-432.
PMID: 38407943
Background: Chimeric antigen receptor T (CAR-T) therapy has substantially revolutionized the clinical outcomes of patients with hematologic malignancies, but the cancer-intrinsic mechanisms underlying resistance to CAR-T cells remain yet to...
2.
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, et al.
Blood Cancer J
. 2023 Apr;
13(1):61.
PMID: 37095094
Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may...
3.
Wu J, Tang L, Du M, Li C, Kou H, Jiang H, et al.
Clin Transl Med
. 2023 Mar;
13(3):e1225.
PMID: 36938989
No abstract available.
4.
Li C, Zhou F, Wang J, Chang Q, Du M, Luo W, et al.
J Hematol Oncol
. 2023 Jan;
16(1):5.
PMID: 36681817
Background: T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared with chimeric antigen receptor-T cells. TCR-T cell therapy is another active field...
5.
Zhang Y, Zhou F, Wu Z, Li Y, Li C, Du M, et al.
Front Immunol
. 2022 Jul;
13:914959.
PMID: 35799791
Clinical Trial Registration: www.clinicaltrials.gov, NCT02965092 and NCT04008251.
6.
Du M, Huang L, Kou H, Li C, Hu Y, Mei H
Front Immunol
. 2022 Jul;
13:898341.
PMID: 35784357
Chimeric antigen receptor T (CAR-T) cell therapy is an attractive strategy for patients with relapsed or refractory hematological malignancies including multiple myeloma (MM). T cells are engineered to attack malignant...
7.
Luo W, Li C, Zhang Y, Du M, Kou H, Lu C, et al.
BMC Cancer
. 2022 Jan;
22(1):98.
PMID: 35073859
Background: Recently, chimeric antigen receptor-modified (CAR) T cell therapy for hematological malignancies has shown clinical efficacy. Hundreds of clinical trials have been registered and lots of studies have shown hematologic...
8.
Luo L, Luo T, Du M, Mei H, Hu Y
J Infect
. 2021 Nov;
84(3):418-467.
PMID: 34808242
No abstract available.
9.
Luo L, Xu M, Du M, Kou H, Liao D, Cheng Z, et al.
Aging (Albany NY)
. 2020 Aug;
12(16):15918-15937.
PMID: 32860672
The ongoing outbreak of Coronavirus Disease 2019 (COVID-19) is hitting the world hard, but the relationship between coagulation disorders and COVID-19 is still not clear. This study aimed to explore...
10.
Du M, Hari P, Hu Y, Mei H
Biomark Res
. 2020 May;
8:13.
PMID: 32426136
The development of chimeric antigen receptor (CAR) T cell immunotherapy has achieved promising results, both in clinical studies and in commercial products for patients with hematologic malignancies. Despite high remission...